Browsing ICR Divisions by author "Cafferty, Fay Helen"
Now showing items 1-7 of 7
-
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Joffe, JK; Cafferty, FH; Murphy, L; Rustin, GJS; Sohaib, SA; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-08-01)PURPOSE: Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation is vital. The ... -
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial.
Birtle, AJ; Jones, R; Chester, J; Lewis, R; Biscombe, K; et al. (American Society of Clinical Oncology (ASCO), 2024-05-01)Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are ... -
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty, FH; White, JD; Shamash, J; Hennig, I; Stenning, SP; et al. (ELSEVIER SCI LTD, 2020-03-01)BACKGROUND: Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, ... -
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love, SB; Cafferty, F; Snowdon, C; Carty, K; Savage, J; et al. (BMC, 2022-09-06)BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are ... -
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen, S; Sauvé, N; Collette, L; Daugaard, G; de Wit, R; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-05-10)PURPOSE: The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and ... -
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
Beyer, J; Collette, L; Sauvé, N; Daugaard, G; Feldman, DR; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-05-10)PURPOSE: The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated ... -
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Joharatnam-Hogan, N; Hatem, D; Cafferty, FH; Petrucci, G; Cameron, DA; et al. (SPRINGERNATURE, 2023-09-07)BACKGROUND: Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet activation, can prevent or delay ...